One To Watch

smartbax

A German antibiotic-focused biotechnology company based in the Munich area. The company operates as an R&D-led organization advancing small-molecule antibacterial programs through preclinical development.

Founding and History

smartbax was founded in 2021 as a spin-out linked to research from the Technical University of Munich. The company completed a €1.2 million seed financing in May 2023 led by Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds, and in October 2025 announced a €4.7 million pre-Series A first closing led by Anobis Asset and Bayern Kapital, with participation from UnternehmerTUM Funding for Innovators and continued support from existing investors. The company has indicated a second closing remained open following the October 2025 announcement.

Therapy Areas and Focus

smartbax is focused on anti-infectives, specifically next-generation small-molecule antibiotics aimed at multi-drug resistant bacteria. The company positions its work around pathogens associated with high medical need, including drug-resistant Gram-negative bacteria and hard-to-treat biofilm-associated infections.

Technology Platforms and Modalities

smartbax’s R&D is centered on small-molecule antibiotics with differentiated mechanisms intended to reduce the likelihood of resistance development. The company describes two main approaches:

A lead small-molecule inhibitor targeting a previously unexplored step in lipopolysaccharide synthesis in Gram-negative bacteria, positioned as an oral candidate and reported to have shown in vivo proof of concept against multi-drug resistant strains.
A platform of small-molecule activators of bacterial hydrolases designed to stimulate enzymatic activity and drive bacterial self-digestion, with stated potential against biofilms and an approach distinct from classical inhibition-based antibiotics.

Key Personnel

Dr. Robert Macsics, CEO and Co-Founder

Marco Janezic, Co-Founder (company-building and business development)

Prof. Dr. Stephan Sieber, Co-Founder and Scientific Founder (Technical University of Munich)

The company also lists a scientific advisory board that includes Prof. Dr. Peter Hammann and Prof. Dr. Rolf Müller.

Strategic Partnerships

smartbax’s partner set is currently weighted toward funding and ecosystem supporters, including venture investors active in antimicrobial resistance and early-stage biotech development. The company’s public disclosures emphasize building a preclinical pipeline intended for later partnering, licensing, or follow-on financing once development candidates and in vivo packages are mature.

FAQ Section

smartbax is developing small-molecule antibiotics with differentiated mechanisms of action, including both classical inhibition of novel bacterial targets and an enzyme-activation strategy intended to kill bacteria by stimulating hydrolase activity.

smartbax is focused on bacterial infections caused by multi-drug resistant pathogens, with programs positioned around priority organisms and infection settings where resistance and biofilms limit current options.

The pipeline includes a lead Gram-negative program targeting lipopolysaccharide synthesis and a second platform of hydrolase activators with activity described across Gram-positive and Gram-negative bacteria, including biofilm settings.

October 2025: smartbax announced a €4.7 million pre-Series A first closing to advance its lead Gram-negative inhibitor through preclinical development and progress hydrolase activator candidates toward lead selection and in vivo proof of concept.
May 2023: the company announced a €1.2 million seed financing to expand its scientific team and advance early preclinical work.

The company has described in vivo proof of concept for its lead lipopolysaccharide-synthesis inhibitor and has positioned its hydrolase activator approach as showing drug-like properties, anti-biofilm activity, and an early profile described as not showing resistance development in its testing to date.

Near-term milestones are preclinical: advancing the lead Gram-negative inhibitor through preclinical development and moving hydrolase activator series toward lead selection and in vivo proof-of-concept packages suitable for IND-enabling planning or partnering discussions.

smartbax is led by a CEO with antibiotic mechanism-of-action and biotech operating experience and was founded with scientific roots in antibacterial discovery at the Technical University of Munich, supported by an advisory network with antibiotic R&D and microbial natural products expertise.

Want to Update your Company's Profile?